Advertisement

Symptomatic relief of constant groaning in progressive supranuclear palsy with escitalopram

      Highlights

      • Groaning is a purposeless behavior due to reduced prefrontal inhibitory control.
      • Groaning is a clinical feature of PSP.
      • There are currently no known treatment options for groaning.
      • In the case presented, escitalopram provided relief and control of groaning.
      • Escitalopram promotes phasic inhibitory control in the basal ganglia in PSP.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stamelou M.
        • Rubio-Agusti I.
        • Quinn N.
        • Bhatia K.
        Characteristic constant groaning in late stage progressive supranuclear palsy: a case report.
        Park. Relat. Disord. 2011; 17: 575-576https://doi.org/10.1016/j.parkreldis.2011.04.015
        • Mainka T.
        • Hidding U.
        • Buhmann C.
        • Haggard P.
        • Ganos C.
        Voluntary inhibition of involuntary groaning in progressive supranuclear palsy: voluntary inhibition of involuntary groaning.
        Mov. Disord. Clin. Pract. 2018; 5: 325-326https://doi.org/10.1002/mdc3.12598
        • Low S.C.
        • Tan A.H.
        • Lim S.-Y.
        Teaching video neuro images : purposeless groaning in progressive supranuclear palsy.
        Neurology. 2017; 88 (e9): e9https://doi.org/10.1212/WNL.0000000000003465
        • Nguyen L.
        • Matsumoto R.R.
        The psychopharmacology of pseudobulbar affect.
        in: Handb. Clin. Neurol., Elsevier. 2019; : 243-251https://doi.org/10.1016/B978-0-444-64012-3.00014-9
        • Chinaglia G.
        • Landwehrmeyer B.
        • Probst A.
        • Palacios J.M.
        Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.
        Neuroscience. 1993; 54: 691-699https://doi.org/10.1016/0306-4522(93)90240-G